Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to $712,218.

  • Amylyx Pharmaceuticals' Gains from Sales and Divestitures rose 68.35% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 68.35%. This contributed to the annual value of $712,218 for FY2024, which is 284.89% up from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Gains from Sales and Divestitures stood at $712,218, which was up 284.89% from $185,045 recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $712,218 for FY2024, and its period low was $185,045 during FY2023.
  • In the last 2 years, Amylyx Pharmaceuticals' Gains from Sales and Divestitures had a median value of $448,632 in 2023 and averaged $448,632.
  • Data for Amylyx Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY surged of 284.89% (in 2024) over the last 5 years.
  • Amylyx Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $185,045 in 2023, then surged by 284.89% to $712,218 in 2024.